CA
NZ
UK
AU
IND
US
Rebecca E. Zorn, an executive officer of Globe Life Inc, filed a Form 144 notice on November 11, 2026, disclosing a proposed sale of 1,000 shares of Globe Life common stock acquired through a stock option exercise on the same date.
Q2 Holdings Inc officer Michael Scott Kerr filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 2,655 shares of Q2 Holdings common stock executed on November 11, 2026, with an aggregate market value of $200,001.15.
Susan Bobulsky, an officer of Adaptive Biotechnologies Corporation, filed a Form 144 on November 12, 2026, notifying the SEC of a proposed sale of 1,875 shares of common stock executed on November 11, 2026.
Health Catalyst Inc. officer Benjamin Landry filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 99,478 shares of common stock executed on November 11, 2026, through Morgan Stanley Smith Barney LLC.
Septerna, Inc. director Alan Ezekowitz filed a Form 144 notice of proposed sale on November 12, 2026, disclosing plans to sell 100,000 shares of Septerna common stock through Morgan Stanley Smith Barney LLC.
Susan Chapman-Hughes, a director of Toast, Inc., filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 6,885 Class A shares of Toast common stock through Fidelity Brokerage Services LLC.
Revolution Medicines, Inc. officer Jack Lee Anders filed a Form 144 notice on November 12, 2026, proposing the sale of 35,750 shares of common stock acquired through stock option exercise on November 11, 2026.
Intercontinental Exchange Inc. officer Mayur Kapani filed a Form 144 notice of proposed sale of 4,272 shares of common stock, with the notice dated November 11, 2026 and submitted to the SEC on November 12, 2026.
Gabriel Mecklenburg, Executive Chairman and Co-Founder of Hinge Health, Inc., filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 200,000 shares of Hinge Health common stock on NYSE.
Director Atul Pande filed a Form 144 notice of proposed sale with the SEC on November 12, 2026, covering 6,000 shares of Immunovant, Inc. common stock acquired through a stock option exercise on November 11, 2026.
Please wait processing your request...